Take a Fresh Look at QVAR® Safety
- QVAR is a prodrug (a pharmacologically inactive compound that is activated in the body after its administration)3
- The active metabolite of QVAR, 17 BMP, has a high protein binding of 94% - 96%3
- QVAR’s small-particle formulation is effective at lower doses than large-particle ICSs:
- - Low incidence of local and systemic side effects4
- - Well tolerated when higher QVAR doses are needed for improved asthma control4
The Safety of QVAR
- QVAR’s safety has been tested and proven for over 8 years5
- In the 9 trials cited in the chart, no cases of oropharyngeal candidiasis were seen6,7
- QVAR is the only small-particle ICS approved for children as young as 5 years of age1,6
References:
- Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(2):S447-S460.
- Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;72:1016-1023.
- Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thor Soc. 2004;1:356-363.
- Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999; 104:1215-1222.
- Data on file. Teva Specialty Pharmaceuticals LLC.
- QVAR Prescribing Information, IVAX Laboratories Inc., 2008.
- Thompson PJ, Davies RJ, Young WF, et al. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med. 1998;92(Suppl A):33-39.
090648